High Resolution Imaging for Analysis of MVNT (HAM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04285125|
Recruitment Status : Recruiting
First Posted : February 26, 2020
Last Update Posted : September 17, 2021
MVNT (multinodular and vacuolating neuronal tumor of the cerebrum) is a benign, recently discovered, neuronal lesion, the incidence of which is unknown.
It seems to predominate in the temporal lobes and presents a characteristic MRI appearance: multiple subcortical nodules, developed at the white substance / gray substance junction, of variable size, well limited, in iso-hyposignal T1, hypersignal T2 and hypersignal FLAIR.
The articles describing this entity report the lack of scalability in MRI during patient monitoring, going in the direction of the benignity of the lesion.
The diagnosis sometimes remains uncertain with current MRI sequences, and the patient risks undergoing invasive surgery to remove a lesion that is actually benign. Hence the importance of developing the most precise diagnostic criteria possible. The contribution of advanced MRI techniques, such as ultra-high resolution sequences in the characterization of these lesions, has not yet been studied.
|Condition or disease||Intervention/treatment|
|Benign Neuronal Desease||Other: cerebral MRI|
|Study Type :||Observational|
|Estimated Enrollment :||33 participants|
|Official Title:||High Resolution Imaging for Analysis of Multinodular and Vacuolating Neuronal Tumor of the Cerebrum|
|Actual Study Start Date :||March 5, 2020|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||March 2025|
- Other: cerebral MRI
Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
- Comparison of the proportion of patients with a central T2 / FLAIR hyposignal visible on standard sequences and on ultra-high resolution sequences. [ Time Frame: Day 1 ]Among the patients with confirmation of the diagnosis of MVNT (Multinodular and Vacuolating Neuronal Tumor) on the characterization MRI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04285125
|Contact: Amelie YAVCHITZ, PhDemail@example.com|
|Contact: Augustin Leclerfirstname.lastname@example.org|
|Groupe Hospitalier Pellegrin||Active, not recruiting|
|Bordeaux, France, 33076|
|Fondation A De Rothschild||Recruiting|
|Paris, France, 75019|
|Contact: Augustin Lecler email@example.com|
|Centre Hospitalier Lyon Sud||Active, not recruiting|
|Pierre Bénite, France, 69495|
|Rennes, France, 35033|
|Contact: Béatrice Carsin-Nicol, MD PhD Beatrice.CARSIN.NICOL@chu-rennes.fr|
|CHU de Rouen||Active, not recruiting|
|Rouen, France, 76000|
|Saint-Herblain, France, 44800|
|Contact: Jesus AGUILLAR, MD PhD firstname.lastname@example.org|
|Hôpital Pierre Paul Riquet, CHU Purpan||Active, not recruiting|
|Toulouse, France, 31059|